Imatinib Koanaa 400 Mg (Imatinib Mesilate)

Imatinib inhibits the ATP‑binding sites of BCR‑ABL, c‑KIT, and PDGFR tyrosine kinases. By blocking these enzymes, it stops downstream signaling that promotes malignant cell proliferation and survival, leading to reduced tumor growth and, in many cases, tumor cell death.

The dose of Imatinib Koanaa 400 Mg is individualized by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and other clinical factors. Patients should follow the exact dosing regimen provided by their healthcare professional.

Safety data for Imatinib in pregnancy and lactation are limited, and the drug may pose risks to the fetus or infant. Women of childbearing potential should discuss contraception and potential risks with their physician, and breastfeeding is generally not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and the necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor and remains a standard first‑line option for CML and Ph+ ALL. Newer agents such as dasatinib and nilotinib have higher potency and may be used when resistance or intolerance to imatinib occurs. Choice of therapy depends on disease characteristics, mutation profile, side‑effect tolerance, and physician judgment.

Imatinib Koanaa 400 Mg tablets should be stored at temperatures below 25 °C, in the original packaging, protected from moisture and direct light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

The medication is taken orally as a whole tablet, usually with a glass of water. It may be taken with or without food, but patients should follow any specific instructions from their prescriber. Swallow the tablet whole; do not crush, split, or chew unless directed by a healthcare professional.

Serious adverse events include hepatotoxicity (liver injury), myelosuppression (low blood counts such as neutropenia, anemia, thrombocytopenia), and cardiotoxicity (heart failure or reduced ejection fraction). Patients should be monitored regularly for liver enzymes, complete blood counts, and cardiac function to detect these risks early.

Imatinib should be avoided in individuals with known hypersensitivity to imatinib or any of its excipients. Caution is also advised for patients with severe hepatic impairment, uncontrolled cardiac disease, or those who are pregnant without a clear medical indication. The prescribing clinician will assess suitability on a case‑by‑case basis.